Arcellx (ACLX) Current Assets (2021 - 2025)
Arcellx's quarterly Current Assets came in at $462.2 million in Q4 2025, down 22.88% year-on-year from $599.3 million in Q4 2024, and down 2.1% quarter-over-quarter from $472.1 million in Q3 2025.
Arcellx has reported Current Assets for 5 years, with the latest figure at $462.2 million in Q4 2025.
- For the quarter ending Q4 2025, Current Assets fell 22.88% year-over-year to $462.2 million; the trailing twelve-month figure through Dec 2025 stood at $462.2 million (down 22.88% YoY), and the FY2025 full-year result was $462.2 million, down 22.88% from the prior year.
- Current Assets for Q4 2025 stood at $462.2 million, down from $472.1 million in the prior quarter.
- The five-year high for Current Assets was $716.4 million in Q4 2023, with the low at $112.8 million in Q4 2021.
- Average Current Assets over 5 years is $459.7 million, with a median of $491.5 million recorded in 2023.
- Year-over-year, Current Assets jumped 168.44% in 2023 and dropped 22.88% in 2025.
- Tracing ACLX's Current Assets over 5 years: stood at $112.8 million in 2021, then soared by 136.56% to $266.9 million in 2022, then jumped by 168.44% to $716.4 million in 2023, then retreated by 16.34% to $599.3 million in 2024, then retreated by 22.88% to $462.2 million in 2025.
- The last three Current Assets figures came in at $462.2 million (Q4 2025), $472.1 million (Q3 2025), and $463.9 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 10.37 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.31 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.25 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 73.04 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 3.59 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 11.73 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.21 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.22 Bn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 462.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 462.18 Mn |
| Sep 30, 2025 | 472.08 Mn |
| Jun 30, 2025 | 463.90 Mn |
| Mar 31, 2025 | 554.15 Mn |
| Dec 31, 2024 | 599.31 Mn |
| Sep 30, 2024 | 587.30 Mn |
| Jun 30, 2024 | 530.20 Mn |
| Mar 31, 2024 | 588.73 Mn |
| Dec 31, 2023 | 716.36 Mn |
| Sep 30, 2023 | 491.46 Mn |
| Jun 30, 2023 | 558.07 Mn |
| Mar 31, 2023 | 571.37 Mn |
| Dec 31, 2022 | 266.86 Mn |
| Sep 30, 2022 | 290.31 Mn |
| Jun 30, 2022 | 325.08 Mn |
| Mar 31, 2022 | 224.39 Mn |
| Dec 31, 2021 | 112.81 Mn |